메뉴 건너뛰기




Volumn 3, Issue 1, 2015, Pages

Pembrolizumab

Author keywords

Immune checkpoint blockade; Lung cancer; Melanoma; Pembrolizumab; Programmed death receptor 1; Programmed death receptor ligand 1

Indexed keywords

AXITINIB; CETUXIMAB; DABRAFENIB; IPILIMUMAB; NIVOLUMAB; PAZOPANIB; PEGINTERFERON ALPHA2B; PEMBROLIZUMAB; PIDILIZUMAB; TALIMOGENE LAHERPAREPVEC; TRAMETINIB; TRASTUZUMAB;

EID: 84998611074     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0078-9     Document Type: Review
Times cited : (184)

References (43)
  • 1
    • 0026700235 scopus 로고
    • Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
    • Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887-95.
    • (1992) EMBO J , vol.11 , pp. 3887-3895
    • Ishida, Y.1    Agata, Y.2    Shibahara, K.3    Honjo, T.4
  • 2
    • 0033180181 scopus 로고    scopus 로고
    • Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor
    • Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141-51.
    • (1999) Immunity , vol.11 , pp. 141-151
    • Nishimura, H.1    Nose, M.2    Hiai, H.3    Minato, N.4    Honjo, T.5
  • 4
    • 0037815272 scopus 로고    scopus 로고
    • PD-1 inhibits antiviral immunity at the effector phase in the liver
    • Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med. 2003;198:39-50.
    • (2003) J Exp Med , vol.198 , pp. 39-50
    • Iwai, Y.1    Terawaki, S.2    Ikegawa, M.3    Okazaki, T.4    Honjo, T.5
  • 8
    • 0037126021 scopus 로고    scopus 로고
    • Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
    • Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293-7.
    • (2002) Proc Natl Acad Sci U S A , vol.99 , pp. 12293-12297
    • Iwai, Y.1    Ishida, M.2    Tanaka, Y.3    Okazaki, T.4    Honjo, T.5    Minato, N.6
  • 9
    • 13844294372 scopus 로고    scopus 로고
    • PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
    • Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2005;17:133-44.
    • (2005) Int Immunol , vol.17 , pp. 133-144
    • Iwai, Y.1    Terawaki, S.2    Honjo, T.3
  • 10
    • 84887862839 scopus 로고    scopus 로고
    • A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
    • Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212-8.
    • (2013) Nat Immunol , vol.14 , pp. 1212-1218
    • Okazaki, T.1    Chikuma, S.2    Iwai, Y.3    Fagarasan, S.4    Honjo, T.5
  • 11
    • 84945554100 scopus 로고    scopus 로고
    • Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
    • Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015. doi: 10.1158/1078-0432.CCR-14-2607.
    • (2015) Clin Cancer Res
    • Patnaik, A.1    Kang, S.P.2    Rasco, D.3    Papadopoulos, K.P.4    Elassaiss-Schaap, J.5
  • 14
    • 84907498839 scopus 로고    scopus 로고
    • Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL)
    • Hamid O, Robert C, Ribas A, Wolchok F, Hodi S, Kefford R, et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). J Clin Oncol. 2014;32(Suppl):3000.
    • (2014) J Clin Oncol , vol.32 , pp. 3000
    • Hamid, O.1    Robert, C.2    Ribas, A.3    Wolchok, F.4    Hodi, S.5    Kefford, R.6
  • 16
    • 84907543029 scopus 로고    scopus 로고
    • Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)
    • LBA9000.
    • Ribas AF, Hodi S, Kefford R, Hamid O, Daud A, Wolchok AD, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol. 2014;32(Suppl):LBA9000.
    • (2014) J Clin Oncol , vol.32
    • Ribas, A.F.1    Hodi, S.2    Kefford, R.3    Hamid, O.4    Daud, A.5    Wolchok, A.D.6
  • 17
    • 84907973066 scopus 로고    scopus 로고
    • Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475
    • Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;32(Suppl):3005.
    • (2014) J Clin Oncol , vol.32 , pp. 3005
    • Kefford, R.1    Ribas, A.2    Hamid, O.3    Robert, C.4    Daud, A.5    Wolchok, J.D.6
  • 20
    • 84938205998 scopus 로고    scopus 로고
    • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
    • Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015. doi: 10.1016/S1470-2045(15)00083-2
    • (2015) Lancet Oncol
    • Ribas, A.1    Puzanov, I.2    Dummer, R.3    Schadendorf, D.4    Hamid, O.5    Robert, C.6
  • 25
    • 84998797367 scopus 로고    scopus 로고
    • Pembrolizumab for Advanced Urothelial Cancer: Updated Results of a Phase 1b Study
    • 2-26-2015. Orlando, Florida: Presented at 2015 American Society of Clinical Oncology Genitourinary Cancers Symposium
    • O'Donnell PH, Plimack ER, Bellmunt J, Berger R, Montgomery B, Heath JK, et al. Pembrolizumab for Advanced Urothelial Cancer: Updated Results of a Phase 1b Study. 2-26-2015. Orlando, Florida: Presented at 2015 American Society of Clinical Oncology Genitourinary Cancers Symposium; 2015.
    • (2015)
    • O'Donnell, P.H.1    Plimack, E.R.2    Bellmunt, J.3    Berger, R.4    Montgomery, B.5    Heath, J.K.6
  • 26
    • 84929342219 scopus 로고    scopus 로고
    • A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
    • San Antonio, Texas: Presented at: San Antonio Breast Cancer Symposium
    • Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. San Antonio, Texas: Presented at: San Antonio Breast Cancer Symposium; 2014.
    • (2014)
    • Nanda, R.1    Chow, L.Q.2    Dees, E.C.3    Berger, R.4    Gupta, S.5    Geva, R.6
  • 28
    • 84938760671 scopus 로고    scopus 로고
    • Clinical Safety and Efficacy of Pembrolizumab (MK-3475) in Patients with Malignant Pleural Mesothelioma (MPM): Preliminary Results from KEYNOTE-028
    • Philadelphia, PA: Presented at: American Association for Cancer Research 2015 Annual Meeting
    • Alley E, Molife LR, Santoro A, Beckey K, Yuan S, Cheng JD, et al. Clinical Safety and Efficacy of Pembrolizumab (MK-3475) in Patients with Malignant Pleural Mesothelioma (MPM): Preliminary Results from KEYNOTE-028. Philadelphia, PA: Presented at: American Association for Cancer Research 2015 Annual Meeting; 2015.
    • (2015)
    • Alley, E.1    Molife, L.R.2    Santoro, A.3    Beckey, K.4    Yuan, S.5    Cheng, J.D.6
  • 30
    • 84997637224 scopus 로고    scopus 로고
    • Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
    • Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother. 2015;3:11.
    • (2015) J Immunother , vol.3 , pp. 11
    • Laubli, H.1    Balmelli, C.2    Bossard, M.3    Pfister, O.4    Glatz, K.5    Zippelius, A.6
  • 31
    • 84895904745 scopus 로고    scopus 로고
    • Mitigating the toxic effects of anticancer immunotherapy
    • Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol. 2014;11:91-9.
    • (2014) Nat Rev Clin Oncol , vol.11 , pp. 91-99
    • Gangadhar, T.C.1    Vonderheide, R.H.2
  • 32
    • 84926416165 scopus 로고    scopus 로고
    • Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
    • Howell M, Lee R, Bowyer S, Fusi A, Lorigan P. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer. 2015;88:117-23.
    • (2015) Lung Cancer , vol.88 , pp. 117-123
    • Howell, M.1    Lee, R.2    Bowyer, S.3    Fusi, A.4    Lorigan, P.5
  • 35
    • 84905991829 scopus 로고    scopus 로고
    • Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): correlation of tumor PD-L1 expression with outcome
    • CT104.
    • Daud AI, Hamid O, Antoni-Ribas F, Hodi S, Hwu WJ, Kefford R, et al. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): correlation of tumor PD-L1 expression with outcome. Cancer Res. 2014;74(Suppl):CT104.
    • (2014) Cancer Res , vol.74
    • Daud, A.I.1    Hamid, O.2    Antoni-Ribas, F.3    Hodi, S.4    Hwu, W.J.5    Kefford, R.6
  • 36
    • 84998781124 scopus 로고    scopus 로고
    • Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients with melanoma treated with pembrolizumab (MK-3475)
    • Zurich, Switzerland: Presented at Society for Melanoma Research 2014 International Congress
    • Daud A, Hamid O, Robert C, Hodi S, Wolchuck JD, Hwu WJ, et al. Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients with melanoma treated with pembrolizumab (MK-3475). Zurich, Switzerland: Presented at Society for Melanoma Research 2014 International Congress; 2014.
    • (2014)
    • Daud, A.1    Hamid, O.2    Robert, C.3    Hodi, S.4    Wolchuck, J.D.5    Hwu, W.J.6
  • 39
    • 84922086584 scopus 로고    scopus 로고
    • Baseline tumor size as an independent prognostic factor for overall survival in paitnets with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475
    • Joseph RW, Elassaiss-Schaap J, Wolchock JD, Joshua AM, Ribas A, Hodi FS, et al. Baseline tumor size as an independent prognostic factor for overall survival in paitnets with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;32(Suppl):305.
    • (2014) J Clin Oncol , vol.32 , pp. 305
    • Joseph, R.W.1    Elassaiss-Schaap, J.2    Wolchock, J.D.3    Joshua, A.M.4    Ribas, A.5    Hodi, F.S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.